Advaxis Provides Additional Information on Clinical Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Britain will not join Canada-led defence bank initiative
Advaxis (ADXS) Provides Update on Clinical Hold Issued by FDA
November 2, 2015 4:49 PM ESTAdvaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today provided additional information about the clinical hold issued by the U.S. Food and Drug Administration (FDA) on the Companys Investigational New Drug (IND) application for axalimogene filolisbac. Since announcing the verbal notification of the clinical hold of axalimogene filolisbac, Advaxis has... More



